- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.07. | RADIOPHARM THERANOSTICS LIMITED: Radiopharm Receives $5.9M R&D Tax Incentive | 1 | ASX | ||
| 30.06. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 30.06. | RADIOPHARM THERANOSTICS LIMITED: Notification regarding unquoted securities - RAD | - | ASX | ||
| 30.06. | RADIOPHARM THERANOSTICS LIMITED: Notification of cessation of securities - RAD | 1 | ASX | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 04.06. | Radiopharm Theranostics stock initiated with buy rating at H.C. Wainwright | 1 | Investing.com | ||
| 03.06. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.06. | RADIOPHARM THERANOSTICS LIMITED: Notification of cessation of securities - RAD | - | ASX | ||
| 01.05. | RADIOPHARM THERANOSTICS LIMITED: Financial Services and Company Secretary Changes | - | ASX | ||
| 23.04. | Radiopharm Theranostics Reports Business Update | 316 | GlobeNewswire (Europe) | Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI... ► Artikel lesen | |
| 23.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | RADIOPHARM THERANOSTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 20.04. | Radiopharm presents early data on HER2-targeted cancer therapy | 1 | Investing.com | ||
| 19.04. | RADIOPHARM THERANOSTICS LIMITED: RAD Initial Findings from Phase 1 177Lu-RAD202 Trial | - | ASX | ||
| 16.04. | Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases | 289 | GlobeNewswire (Europe) | Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial... ► Artikel lesen | |
| 16.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 15.04. | RADIOPHARM THERANOSTICS LIMITED: RAD Completes Enrollment in Phase 2b Trial of RAD 101 | - | ASX | ||
| 08.04. | Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial | 427 | GlobeNewswire (Europe) | SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 08.04. | RADIOPHARM THERANOSTICS LIMITED: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3 | 1 | ASX | ||
| 07.04. | Radiopharm schließt Liefervertrag mit Siemens Healthineers für Hirntumor-Diagnostikum | 80 | Investing.com Deutsch | ||
| 07.04. | Radiopharm signs supply deal with Siemens for brain cancer drug | 14 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,130 | -0,83 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,000 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,186 | -0,67 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,294 | -7,84 % | NurExone-Tochter Exo-Top nimmt mexikanischen Exosomenmarkt ins Visier | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,253 | -0,16 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| REDHILL BIOPHARMA | 0,705 | 0,00 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,385 | -2,65 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 13,385 | -3,77 % | JPMorgan nimmt NovoCure-Bewertung mit "Neutral" wieder auf | ||
| REVOLUTION MEDICINES | 163,45 | +0,49 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,050 | +2,55 % | Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales | ||
| ROCKET PHARMACEUTICALS | 3,020 | +0,33 % | ROCKET PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PALISADE BIO | 1,965 | -0,25 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,850 | -0,39 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial | Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 1,220 | 0,00 % | Outlook Therapeutics, Inc. - 8-K, Current Report | ||
| REGENXBIO | 8,920 | +3,34 % | REGENXBIO stock dips on $100M equity offering |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,130 (-2,93 %) liegt der Kurs bei 4,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.